http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 19 Oct 2026 18:43:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DEXCOM+INC++++++++++++++++For%3A+Oct+15++Filed+by%3A+Brown+Michael+Jon/27205000.html si-local-file:///var/storage/secattach/20261019/27205000.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DEXCOM+INC++++++++++++++++For%3A+Oct+15++Filed+by%3A+Brown+Michael+Jon/27205000.html Mon, 19 Oct 2026 18:43:00 -0400 DXCM http://www.streetinsider.com/SEC+Filings/Form++144++++++++DEXCOM+INC+++++++++++++++++++++++++++++Filed+by%3A+Brown+Michael+Jon/27193281.html si-local-file:///var/storage/secattach/20261015/27193281.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++DEXCOM+INC+++++++++++++++++++++++++++++Filed+by%3A+Brown+Michael+Jon/27193281.html Thu, 15 Oct 2026 16:02:00 -0400 DXCM http://www.streetinsider.com/Press+Releases/Landmark+Dexcom+CONNECT+Study+Published+in+The+New+England+Journal+of+Medicine%2C+Redefining+the+Standard+of+Care+for+People+with+Type+2+Diabetes+Not+on+Insulin/27187856.html <ul class="bwlistdisc"> <li> <i>Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, dating back to the creation of the CGM category.</i> </li> <li> <i>Randomized controlled trial demonstrates Dexcom G7 significantly reduces A1C and improves glucose control compared with routine care.</i> </li> <li> <i>Benefits observed across a broad range of participants, including those taking GLP-1 medications.1</i> </li> <li> <i>Findings support the role of CGM earlier in Type 2 diabetes care for all people, including those over the age of 65.</i> </li> </ul> <p> SAN DIEGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54622461&amp;newsitemid=20261014236618&amp;lan=en-US&amp;anchor=DexCom%2C+Inc.&amp;index=1&amp;md5=6be88119b1caf4f9bc22a21a00c0fbe4" shape="rect">DexCom, Inc.</a> (NASDAQ: DXCM), http://www.streetinsider.com/Press+Releases/Landmark+Dexcom+CONNECT+Study+Published+in+The+New+England+Journal+of+Medicine%2C+Redefining+the+Standard+of+Care+for+People+with+Type+2+Diabetes+Not+on+Insulin/27187856.html Wed, 14 Oct 2026 17:10:00 -0400 DXCM http://www.streetinsider.com/Business+Wire/Landmark+Dexcom+CONNECT+Study+Published+in+The+New+England+Journal+of+Medicine%2C+Redefining+the+Standard+of+Care+for+People+with+Type+2+Diabetes+Not+on+Insulin/27187856.html <ul class="bwlistdisc"> <li> <i>Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, dating back to the creation of the CGM category.</i> </li> <li> <i>Randomized controlled trial demonstrates Dexcom G7 significantly reduces A1C and improves glucose control compared with routine care.</i> </li> <li> <i>Benefits observed across a broad range of participants, including those taking GLP-1 medications.1</i> </li> <li> <i>Findings support the role of CGM earlier in Type 2 diabetes care for all people, including those over the age of 65.</i> </li> </ul> <p> SAN DIEGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54622461&amp;newsitemid=20261014236618&amp;lan=en-US&amp;anchor=DexCom%2C+Inc.&amp;index=1&amp;md5=6be88119b1caf4f9bc22a21a00c0fbe4" shape="rect">DexCom, Inc.</a> (NASDAQ: DXCM), http://www.streetinsider.com/Business+Wire/Landmark+Dexcom+CONNECT+Study+Published+in+The+New+England+Journal+of+Medicine%2C+Redefining+the+Standard+of+Care+for+People+with+Type+2+Diabetes+Not+on+Insulin/27187856.html Wed, 14 Oct 2026 17:10:00 -0400 DXCM http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html <p>While for some time in August there was optimism about the U.S. MedTech universe, post September, the whole sector has gone back to taking a beating, notes Citi in its preview into Q3 earnings of the sector. Firm analysts say they have low expectations from the earnings print, but will be looking for pockets of growth and recovery into 2027.</p><p>Procedure volumes, hospital capex, the macro environment, and idiosyncratic overhangs have all been blamed for weighing the sector down, but these all seem like rationalisations, the firm noted. Previously, investors were focusing on an island of medtech stocks with at least http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q3+earnings+preview/27172882.html Sun, 11 Oct 2026 15:00:00 -0400 ABT BSX DXCM EW SGHT SYK ZBH http://www.streetinsider.com/Press+Releases/Dexcom+Schedules+Third+Quarter+2026+Earnings+Release+and+Conference+Call+for+October+29%2C+2026+at+4%3A30+p.m.+Eastern+Time/27158464.html <p> SAN DIEGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54617168&amp;newsitemid=20261007440672&amp;lan=en-US&amp;anchor=DexCom%2C+Inc.&amp;index=1&amp;md5=2030a542a1a19355df6b4da3989449ec" shape="rect">DexCom, Inc.</a> (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.dexcom.com%2F&amp;esheet=54617168&amp;newsitemid=20261007440672&amp;lan=en-US&amp;anchor=investors.dexcom.com&amp;index=2&amp;md5=54394c29f162c9eda94ddb32cf3571e5" shape="rect">investors.dexcom.com</a> and will be archived there for future reference.</p><p>To listen to the conference call, please http://www.streetinsider.com/Press+Releases/Dexcom+Schedules+Third+Quarter+2026+Earnings+Release+and+Conference+Call+for+October+29%2C+2026+at+4%3A30+p.m.+Eastern+Time/27158464.html Wed, 07 Oct 2026 08:30:00 -0400 DXCM http://www.streetinsider.com/Business+Wire/Dexcom+Schedules+Third+Quarter+2026+Earnings+Release+and+Conference+Call+for+October+29%2C+2026+at+4%3A30+p.m.+Eastern+Time/27158464.html <p> SAN DIEGO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54617168&amp;newsitemid=20261007440672&amp;lan=en-US&amp;anchor=DexCom%2C+Inc.&amp;index=1&amp;md5=2030a542a1a19355df6b4da3989449ec" shape="rect">DexCom, Inc.</a> (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.dexcom.com%2F&amp;esheet=54617168&amp;newsitemid=20261007440672&amp;lan=en-US&amp;anchor=investors.dexcom.com&amp;index=2&amp;md5=54394c29f162c9eda94ddb32cf3571e5" shape="rect">investors.dexcom.com</a> and will be archived there for future reference.</p><p>To listen to the conference call, please http://www.streetinsider.com/Business+Wire/Dexcom+Schedules+Third+Quarter+2026+Earnings+Release+and+Conference+Call+for+October+29%2C+2026+at+4%3A30+p.m.+Eastern+Time/27158464.html Wed, 07 Oct 2026 08:30:00 -0400 DXCM http://www.streetinsider.com/New+Coverage/Barclays+Starts+DexCom+%28DXCM%29+at+Overweight/27155838.html <p>Barclays analyst Matt Miksic initiates coverage on DexCom (NASDAQ: DXCM) with a Overweight rating and a price target of $115.00.</p> <p>For an analyst ratings summary and ratings history on DexCom <a href="http://www.streetinsider.com/rating_history.php?q=DXCM">click here</a>. For more ratings news on DexCom <a href="http://www.streetinsider.com/stock_lookup_news.php?q=DXCM&amp;type=analyst">click here</a>.</p> <p>Shares of DexCom closed at $86.90 yesterday.</p> http://www.streetinsider.com/New+Coverage/Barclays+Starts+DexCom+%28DXCM%29+at+Overweight/27155838.html Tue, 06 Oct 2026 16:25:04 -0400 DXCM http://www.streetinsider.com/Press+Releases/Dexcom+U+Enters+Season+5+With+a+Record+Roster+and+Evidence+That+Diabetes+Stigma+Among+Young+Athletes+Is+Fading/27152956.html <ul class="bwlistdisc"><li><i>First-of-its-kind NIL program features 27 athletes with Type 1 diabetes across 13 sports, marking the program’s largest roster to date</i></li><li><i>Dexcom will host “Dexcom U Days” this fall to drive meaningful community and mentorship between college and young athletes with diabetes</i></li><li><i>New research shows young adults with Type 1 diabetes are sticking with sports longer and feeling less isolated than they did since the launch of Dexcom U in 2022</i><i>1</i></li></ul> <p> SAN DIEGO--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54616804&amp;newsitemid=20261006690020&amp;lan=en-US&amp;anchor=DEXCOM&amp;index=1&amp;md5=1402a80c9420bde1a3bf42c45cb33442" shape="rect">DEXCOM</a>, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of <a target="_blank" http://www.streetinsider.com/Press+Releases/Dexcom+U+Enters+Season+5+With+a+Record+Roster+and+Evidence+That+Diabetes+Stigma+Among+Young+Athletes+Is+Fading/27152956.html Tue, 06 Oct 2026 09:00:00 -0400 DXCM http://www.streetinsider.com/Business+Wire/Dexcom+U+Enters+Season+5+With+a+Record+Roster+and+Evidence+That+Diabetes+Stigma+Among+Young+Athletes+Is+Fading/27152956.html <ul class="bwlistdisc"><li><i>First-of-its-kind NIL program features 27 athletes with Type 1 diabetes across 13 sports, marking the program’s largest roster to date</i></li><li><i>Dexcom will host “Dexcom U Days” this fall to drive meaningful community and mentorship between college and young athletes with diabetes</i></li><li><i>New research shows young adults with Type 1 diabetes are sticking with sports longer and feeling less isolated than they did since the launch of Dexcom U in 2022</i><i>1</i></li></ul> <p> SAN DIEGO--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54616804&amp;newsitemid=20261006690020&amp;lan=en-US&amp;anchor=DEXCOM&amp;index=1&amp;md5=1402a80c9420bde1a3bf42c45cb33442" shape="rect">DEXCOM</a>, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of <a target="_blank" http://www.streetinsider.com/Business+Wire/Dexcom+U+Enters+Season+5+With+a+Record+Roster+and+Evidence+That+Diabetes+Stigma+Among+Young+Athletes+Is+Fading/27152956.html Tue, 06 Oct 2026 09:00:00 -0400 DXCM http://www.streetinsider.com/Press+Releases/Dexcom+U+Enters+Season+5+With+a+Record+Roster+and+Evidence+That+Diabetes+Stigma+Among+Young+Athletes+Is+Fading/27154694.html <ul class="bwlistdisc"><li><i>First-of-its-kind NIL program features 27 athletes with Type 1 diabetes across 13 sports, marking the program’s largest roster to date</i></li><li><i>Dexcom will host “Dexcom U Days” this fall to drive meaningful community and mentorship between college and young athletes with diabetes</i></li><li><i>New research shows young adults with Type 1 diabetes are sticking with sports longer and feeling less isolated than they did since the launch of Dexcom U in 2022</i><i>1</i></li></ul> <p> SAN DIEGO--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54616804&amp;newsitemid=20261006690020&amp;lan=en-US&amp;anchor=DEXCOM&amp;index=1&amp;md5=1402a80c9420bde1a3bf42c45cb33442" shape="rect">DEXCOM</a>, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of <a target="_blank" http://www.streetinsider.com/Press+Releases/Dexcom+U+Enters+Season+5+With+a+Record+Roster+and+Evidence+That+Diabetes+Stigma+Among+Young+Athletes+Is+Fading/27154694.html Tue, 06 Oct 2026 09:00:00 -0400 DXCM http://www.streetinsider.com/Business+Wire/Dexcom+U+Enters+Season+5+With+a+Record+Roster+and+Evidence+That+Diabetes+Stigma+Among+Young+Athletes+Is+Fading/27154694.html <ul class="bwlistdisc"><li><i>First-of-its-kind NIL program features 27 athletes with Type 1 diabetes across 13 sports, marking the program’s largest roster to date</i></li><li><i>Dexcom will host “Dexcom U Days” this fall to drive meaningful community and mentorship between college and young athletes with diabetes</i></li><li><i>New research shows young adults with Type 1 diabetes are sticking with sports longer and feeling less isolated than they did since the launch of Dexcom U in 2022</i><i>1</i></li></ul> <p> SAN DIEGO--(BUSINESS WIRE)--</p> <p class="bwalignl"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54616804&amp;newsitemid=20261006690020&amp;lan=en-US&amp;anchor=DEXCOM&amp;index=1&amp;md5=1402a80c9420bde1a3bf42c45cb33442" shape="rect">DEXCOM</a>, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of <a target="_blank" http://www.streetinsider.com/Business+Wire/Dexcom+U+Enters+Season+5+With+a+Record+Roster+and+Evidence+That+Diabetes+Stigma+Among+Young+Athletes+Is+Fading/27154694.html Tue, 06 Oct 2026 09:00:00 -0400 DXCM